An interventional study of Circulating Tumor DNA (ctDNA) Assay in Lung Cancer and EGFR Gene Mutation, sponsored by Dana-Farber Cancer Institute. Recruiting at 6 sites in United States. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute — 7 open to participants now, 9 under way, none of them phase 3. Lung Neoplasms · Dana-Farber Cancer Institute.
Among the 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 23rd registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →7 of the 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Healthy volunteers
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7
First in 1998; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 33 across the 19 interventional studies, 337 across the 6 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
3 of the studies in Lung Neoplasms by Dana-Farber Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07412041Dana-Farber Cancer InstitutePrecise Exercise Regimen for Cancer Care (PERCC): A Pilot Study | 2027-03-30 |
| NCT06716580Dana-Farber Cancer InstituteEQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations | 2027-09-01 |
| NCT05587439Dana-Farber Cancer InstituteInvestigating Hereditary Risk In Thoracic Cancers (INHERIT) | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening.
The name of the test used in this research study is:
-Circulating free DNA (cfDNA) Assay
The goal of this research study is to evaluate the feasibility of a novel EGFR blood plasma ctDNA screening test among East Asian and Latinx participants at risk for lung cancer and ineligible for regular lung cancer screening. The test looks for a gene change called Epidermal Growth Factor Receptor (EGFR), specifically EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. This study seeks to determine if it is possible to use the blood test to detect this type of lung cancer that might not yet show symptoms.
The research study procedures include screening for eligibility, in-clinic visits, blood tests, and an optional questionnaire and/or focus group.
It is expected that about 1000 people will participate in the blood sample collection, 100 individuals in the survey, and 20 individuals in the focus groups.
The criteria were revised on the registry on Nov 13, 2026. See what changed
Inclusion Criteria (Aims 1, 2, and 3)
Group 1 - Healthy Individuals (50-80 years of age):
Non-tobacco using (currently). Self-identify as East Asian (including Southeast Asian) or Latinx/Hispanic. East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, or Malaysian.
Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, or Filipino.
Latinx/Hispanic includes those who self-identify as a person of Central or South American or Caribbean culture or origin.
Countries of origin include:
East Asian: China, Japan, Korea, Mongolia, Singapore, Taiwan.
Southeast Asian: Brunei, Cambodia, Philippines, Laos, Malaysia, Myanmar, Thailand, Timor-Leste, Vietnam.
Latinx/Hispanic: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Spain, Suriname, Trinidad and Tobago, Uruguay, Venezuela.
Group 2 - At-Risk Individuals (40-80 years of age):
Non-tobacco using (currently).
Individuals of any race or ethnicity who meet at least one of the following criteria:
Family history of any EGFR-mutant lung cancer. Personal history of chest radiation. History of tuberculosis (TB) infection, asthma requiring daily inhaled , or chronic bronchitis.
Symptoms of lung cancer for the past month, including unexplained weight loss, voice hoarseness, cough or worsening cough, or dyspnea or worsening dyspnea.
Excluding individuals who concurrently present with a viral infection, runny nose, sore throat, or productive cough with green or yellow sputum.
Additional Inclusion Criteria for Groups 1 and 2:
Aims 1 and 2: Able to complete and understand the study's in their preferred language.
Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.
Exclusion Criteria (Aims 1, 2, and 3) for Groups 1 and 2:
Having had a chest CT scan in the last 12 months or having an anticipated chest CT scan during the enrollment period.
Having a current cancer or history of cancer within the last 3 years, excluding localized skin cancer, breast ductal carcinoma in situ, and localized prostate cancer.
Hemoptysis. More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use. Adults unable to provide informed consent. Individuals younger than 40 years of age. Prisoners. Pregnant women. Personal diagnosis of lung cancer or testing for clinical suspicion of lung cancer.
Not able to comply with study requirements.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will be asked to provide blood samples and are administered a baseline questionnaire. The blood sample will be tested using the investigational ctDNA assay. If the investigational test is positive, these participants will be followed up by CLIA verification of results. A positive CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months. Participants will be notified of results. Additionally, participants may participant in optional studies: 1) One-time survey regarding perception of lung cancer screening and ctDNA testing, 2) Virtual focus group, 3) Blood banking study
Device: Circulating Tumor DNA (ctDNA) Assay
Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.
Detection Rate of Non-Small Cell Lung Cancer
The proportion of participants with a positive assay result who are subsequently diagnosed with lung cancer through clinical pathology, among all participants tested with the assay.
Time frame: 2 years
Testing Turnaround Time
The duration from the time of blood draw to the release of the ctDNA testing results to the study team.
Time frame: Up to 2 years
Recruitment Acceptability
Determining proportion of screened patients who are eligible and who consent to the trial at each collaboration site
Time frame: Up to 2 years
Barriers to Sample Acquisition
Examining barriers impeding scale-up of sample collection, handling, and delivery
Time frame: Up to 2 years
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 29 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute →